UBS raises Iovanace Biotherapeutics price target to $8 on revenue outlook
Open the sourceReported by Investing.com, investing.com, 3 November 2026, by Investing.com
40Impact 40 of 100, routine
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Muhabbit only has the headline for this one. The full report is at investing.com.
Named in this story
Iovanace Biotherapeutics, UBS